g4靶向三唑吲哚支架对致癌c-KIT和KRAS的双重转录抑制诱导白血病细胞的合成致死

IF 6.8 1区 医学 Q1 CHEMISTRY, MEDICINAL
Tathagato Bhattacharyya,Sarmistha Pal,Sayantan Pradhan,Jyotirmayee Dash
{"title":"g4靶向三唑吲哚支架对致癌c-KIT和KRAS的双重转录抑制诱导白血病细胞的合成致死","authors":"Tathagato Bhattacharyya,Sarmistha Pal,Sayantan Pradhan,Jyotirmayee Dash","doi":"10.1021/acs.jmedchem.5c00736","DOIUrl":null,"url":null,"abstract":"In this study, we report the design and synthesis of a triazolyl-indole derivative, TI12, which induces synthetic lethality in K562 leukemia cells by preferentially targeting G-quadruplexes (G4s) in the promoter regions of c-KIT1 and KRAS. Among a series of synthesized triazolyl-indole derivatives, TI12 exhibits submicromolar affinity for these G4s, as confirmed by biophysical assays along with molecular docking and simulations. Biological studies demonstrate that TI12 represses c-KIT and KRAS transcription, leading to G1-phase cell cycle arrest, ROS-mediated DNA damage, and apoptosis. Notably, TI12 does not affect cells overexpressing either c-KIT or KRAS, suggesting that its cytotoxicity arises from the simultaneous suppression of both oncogenes. In vivo studies depicted the potential antitumor efficacy of TI12 with minimal systemic toxicity. This study highlights the potential of G4-targeting ligands as synthetic lethal agents, offering a novel strategy for disrupting cooperative oncogenic pathways in leukemia.","PeriodicalId":46,"journal":{"name":"Journal of Medicinal Chemistry","volume":"64 1","pages":""},"PeriodicalIF":6.8000,"publicationDate":"2025-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Dual Transcriptional Repression of Oncogenic c-KIT and KRAS by G4-Targeting Triazolyl-Indole Scaffolds Induces Synthetic Lethality in Leukemia Cells.\",\"authors\":\"Tathagato Bhattacharyya,Sarmistha Pal,Sayantan Pradhan,Jyotirmayee Dash\",\"doi\":\"10.1021/acs.jmedchem.5c00736\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"In this study, we report the design and synthesis of a triazolyl-indole derivative, TI12, which induces synthetic lethality in K562 leukemia cells by preferentially targeting G-quadruplexes (G4s) in the promoter regions of c-KIT1 and KRAS. Among a series of synthesized triazolyl-indole derivatives, TI12 exhibits submicromolar affinity for these G4s, as confirmed by biophysical assays along with molecular docking and simulations. Biological studies demonstrate that TI12 represses c-KIT and KRAS transcription, leading to G1-phase cell cycle arrest, ROS-mediated DNA damage, and apoptosis. Notably, TI12 does not affect cells overexpressing either c-KIT or KRAS, suggesting that its cytotoxicity arises from the simultaneous suppression of both oncogenes. In vivo studies depicted the potential antitumor efficacy of TI12 with minimal systemic toxicity. This study highlights the potential of G4-targeting ligands as synthetic lethal agents, offering a novel strategy for disrupting cooperative oncogenic pathways in leukemia.\",\"PeriodicalId\":46,\"journal\":{\"name\":\"Journal of Medicinal Chemistry\",\"volume\":\"64 1\",\"pages\":\"\"},\"PeriodicalIF\":6.8000,\"publicationDate\":\"2025-09-25\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Medicinal Chemistry\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1021/acs.jmedchem.5c00736\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CHEMISTRY, MEDICINAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Medicinal Chemistry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1021/acs.jmedchem.5c00736","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0

摘要

在这项研究中,我们设计和合成了一种三唑基吲哚衍生物TI12,它通过优先靶向c-KIT1和KRAS启动子区域的g -四联体(G4s)诱导K562白血病细胞的合成致死。在一系列合成的三唑基吲哚衍生物中,TI12对这些G4s具有亚微摩尔亲和力,这得到了生物物理实验以及分子对接和模拟的证实。生物学研究表明,TI12抑制c-KIT和KRAS转录,导致g1期细胞周期阻滞、ros介导的DNA损伤和细胞凋亡。值得注意的是,TI12不影响过表达c-KIT或KRAS的细胞,这表明其细胞毒性来自于同时抑制两种致癌基因。体内研究表明,TI12具有潜在的抗肿瘤功效,且具有最小的全身毒性。这项研究强调了g4靶向配体作为合成致死药物的潜力,为破坏白血病的协同致癌途径提供了一种新的策略。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Dual Transcriptional Repression of Oncogenic c-KIT and KRAS by G4-Targeting Triazolyl-Indole Scaffolds Induces Synthetic Lethality in Leukemia Cells.
In this study, we report the design and synthesis of a triazolyl-indole derivative, TI12, which induces synthetic lethality in K562 leukemia cells by preferentially targeting G-quadruplexes (G4s) in the promoter regions of c-KIT1 and KRAS. Among a series of synthesized triazolyl-indole derivatives, TI12 exhibits submicromolar affinity for these G4s, as confirmed by biophysical assays along with molecular docking and simulations. Biological studies demonstrate that TI12 represses c-KIT and KRAS transcription, leading to G1-phase cell cycle arrest, ROS-mediated DNA damage, and apoptosis. Notably, TI12 does not affect cells overexpressing either c-KIT or KRAS, suggesting that its cytotoxicity arises from the simultaneous suppression of both oncogenes. In vivo studies depicted the potential antitumor efficacy of TI12 with minimal systemic toxicity. This study highlights the potential of G4-targeting ligands as synthetic lethal agents, offering a novel strategy for disrupting cooperative oncogenic pathways in leukemia.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Journal of Medicinal Chemistry
Journal of Medicinal Chemistry 医学-医药化学
CiteScore
4.00
自引率
11.00%
发文量
804
审稿时长
1.9 months
期刊介绍: The Journal of Medicinal Chemistry is a prestigious biweekly peer-reviewed publication that focuses on the multifaceted field of medicinal chemistry. Since its inception in 1959 as the Journal of Medicinal and Pharmaceutical Chemistry, it has evolved to become a cornerstone in the dissemination of research findings related to the design, synthesis, and development of therapeutic agents. The Journal of Medicinal Chemistry is recognized for its significant impact in the scientific community, as evidenced by its 2022 impact factor of 7.3. This metric reflects the journal's influence and the importance of its content in shaping the future of drug discovery and development. The journal serves as a vital resource for chemists, pharmacologists, and other researchers interested in the molecular mechanisms of drug action and the optimization of therapeutic compounds.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信